# Northislet

> Northislet is a VC fund in Stockholm backing Biotechnology, Biopharma and Pharmaceutical. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Stockholm, Sweden
- Total investments: 2
- Last investment: Oct 2024
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/northislet/about/
- Website: http://www.northislet.com

Northislet is a Nordic growth investor focused on investments in technology and life sciences. Northislet invests significantly in tiny growing enterprises where active ownership can increase long-term value. They select early-stage Tech and Life Science firms and use an active strategy, leveraging our skills and network, to assist in increasingthe total value of our investments.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Biopharma | 1 | 50% |
| Pharmaceutical | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Funding Round | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AAX Biotech | AAX Biotech specializes in next-generation antibody therapeutics through our two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. OurTechnologies: Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics.Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies. | $681.9K | Seed | Oct 02, 2024 |  |
| BioLamina | BioLamina is a biotechnology company with a global presence, offering cell culture matrices for primary cells. |  |  | Sep 12, 2023 |  |

2 of 2 investments shown.

## Co-investors
- [Bure Equity AB](https://shizune.co/investors/profile/bure-equity-ab) — VC Fund, 1 deal together
- [HJKK Didrikson](https://shizune.co/investors/profile/hjkk-didrikson) — VC Fund, 1 deal together
- [Karolinska Institutet Holding](https://shizune.co/investors/profile/karolinska-institutet-holding) — VC Fund, 1 deal together
- [Lauxera Capital Partners](https://shizune.co/investors/profile/lauxera-capital-partners) — VC Fund, 1 deal together
- [Life Science Invest](https://shizune.co/investors/profile/life-science-invest) — VC Fund, 1 deal together
- [Phase2Phase Biopharma](https://shizune.co/investors/profile/phase2phase-biopharma) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Chalmers Ventures AB](https://shizune.co/investors/profile/chalmers-ventures) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Sweden](https://shizune.co/investors/biotechnology-investors-sweden)
- [Biotechnology VC Funds in Sweden](https://shizune.co/investors/biotechnology-vc-funds-sweden)
- [Biotech Investors in Sweden](https://shizune.co/investors/biotech-investors-sweden)
- [Biotech VC Funds in Sweden](https://shizune.co/investors/biotech-vc-funds-sweden)

## FAQ

### What does Northislet invest in?

Northislet invests primarily in Biotechnology, Biopharma and Pharmaceutical startups, most often at Seed and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Northislet last invest?

The most recent investment recorded for Northislet closed in Oct 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co